This retrospective cohort study emulating the CREDENCE and DAPA-CKD trials suggested that, compared with GLP-1 RA use, SGLT2 inhibitor use was associated with a 19% lower risk of composite anemia outcomes. This evidence concerns the gene GLP1R and anemia (phenotype).